Not available
Quote | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
Last: | $10.17 |
---|---|
Change Percent: | 0.92% |
Open: | $9.67 |
Close: | $10.17 |
High: | $10.18 |
Low: | $9.67 |
Volume: | 30,440 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
2024-07-17 15:39:52 ET More on Atara Biotherapeutics Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy Atara Biotherapeutics announces reverse split to regain Nasdaq compliance Seeking Alpha’s Quant Rating on Atara Bi...
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Message Board Posts | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ATRA News Article - Atara Biotherapeutics to Announce First Quarter 2023 Financial Res | whytestocks | investorshangout | 05/01/2023 8:20:47 PM |
whytestocks: $ATRA News Article - Atara Biotherapeutics to Announce Fourth Quarter and Full Year 202 | whytestocks | investorshangout | 02/06/2023 3:35:45 PM |
whytestocks: $ATRA News Article - CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo(TM) (ta | whytestocks | investorshangout | 10/14/2022 12:05:54 PM |
znewcar1: ATRA 25% v6,2M c5.84 f94,4M H5.87 ML2.83 | znewcar1 | investorshangout | 08/12/2022 8:46:00 PM |
znewcar1: ATRA 29% v14,5M c4.69 f93,4M H4.92 ML2.83 gap down | znewcar1 | investorshangout | 08/09/2022 8:10:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...